Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.

@article{Navarro1998CerebrospinalFC,
  title={Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.},
  author={J. Alberto Romero Navarro and F{\'e}lix Javier Jim{\'e}nez-Jim{\'e}nez and Jos{\'e} A. Molina and Juli{\'a}n Benito-Le{\'o}n and Emilio Cisneros and Teresa Gasalla and M. Ort{\'i}-Pareja and Antonio Tall{\'o}n-Barranco and F de Bustos and J. Olier Arenas},
  journal={Journal of the neurological sciences},
  year={1998},
  volume={155 1},
  pages={92-4}
}
We measured CSF and plasma levels of cGMP in 22 patients with Parkinson's disease (PD) and in 28 age and sex-matched controls. PD patients had similar plasma cGMP levels than those of controls, although they showed a non-significant trend towards higher CSF cGMP levels (P=0.07). PD patients treated with levodopa showed significantly higher CSF cGMP levels than those not treated with this drug (P<0.01), and controls (P<0.01). However, treatment with dopamine agonists did not influence CSF cGMP… CONTINUE READING